Avsar.

Healthcare · Pharmaceuticals

Torrent Pharmaceuticals Ltd (TORNTPHARM)

₹4,961.50

Mkt cap
₹1.89L Cr
P/E ratio
86.10
P/B
20.01
Div yield
0.77%
ROE
27.40%
ROCE
15.20%
EPS (TTM)
₹57.62
Book value
₹248
52W range
3,504–5,065
Sector
Healthcare

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. [1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses. [2]

NSE TORNTPHARMBSE 500420www.torrentpharma.com
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−2.05% from high
₹4,962
₹3,504+41.62% from low₹5,065
Current
₹4,961.50
Prev close
₹4,978.90
Day
−0.35%
Price performance
1D
−0.35%
1W
−0.88%
1M
+9.86%
3M
+20.51%
6M
+24.76%
1Y
+41.57%
YTD
+27.70%

Financials

F
Revenue, profit & margin
P/E ratio
86.1×
TORNTPHARM is 154% above the sector median of 33.9×
TORNTPHARM86.1×
Sector median33.9×
 Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Trend
Sales2,4912,5912,6602,7322,7452,8592,8892,8092,9593,1783,3023,3034,197
Expenses1,7641,8001,8351,8631,8621,9551,9501,8951,9952,1462,2192,2152,841
Operating Profit7277918258698839049399149641,0321,0831,0881,356
OPM %29%31%31%32%32%32%32%33%33%32%33%33%32%
Other Income93426553124-1633-42-37-40-23-83
Interest10710391808075645756564845236
Depreciation196191201213203197198199201201204206508
Profit before tax433531559631631656661691665738791814529
Tax %34%29%31%30%29%30%31%27%25%26%25%22%31%
Net Profit287378386443449457453503498548591635364
EPS in Rs8.4811.1711.4113.0913.2713.5013.3814.8614.7116.1917.4618.7610.76
Raw PDF

Earnings

EResults dates & reactions
Next results
30 Jul '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.81% · closed higher next day 31 of last 65
 Q1FY24Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25†Q1FY26Q2FY26Q3FY26Q4FY26
Broadcast7 Aug '23◦25 Oct '232 Feb '24◦24 May '24◦23 Jul '24◦25 Oct '24◦24 Jan '25◦20 May '25◦28 Jul '25◦7 Nov '25◦13 Feb '26◦22 May '26◦
Earnings day−0.54%+2.39%+4.67%+1.63%+0.23%−3.38%+2.75%+1.47%+4.01%+6.63%+4.50%+1.93%
+1 day+1.09%+0.66%+3.37%+2.07%−1.70%−6.33%+2.04%−0.91%+2.97%+6.87%+4.42%−0.76%
+5 days−3.17%+2.28%+3.72%+2.50%+1.05%−7.24%−1.25%−2.33%−0.93%+6.69%+5.63%−3.75%
+15 days−4.71%+8.64%+3.90%+10.50%+6.69%−9.64%−7.22%−1.10%+1.13%+4.38%+8.58%−0.43%
+30 days−8.63%+9.38%−0.96%+12.38%+9.68%−3.06%−5.46%+3.33%−1.08%+6.59%−2.23%+8.47%
FilingXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLPDFPDFXBRLXBRL

Corporate actions

CLast 6 months
KindValueEx-dateRecord
dividend
Dividend - Rs 9 Per Share
9.0029 May '2629 May '26
dividend
Interim Dividend - Rs 29 Per Share
29.0018 Feb '2619 Feb '26

Shareholding

Sas of Jul 2026
60.78%Promoter
Promoters60.78%7.53
FIIs17.97%2.53
DIIs12.77%3.04
Public8.39%1.97
Government0.09%0.01
Ownership trend

Peers

P7 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,941.1037.484,65,7230.82%2,710+13.58%14,612+12.76%20.53%
Divi's Lab.₹7,248.5073.381,92,4890.41%751+13.44%2,831+9.52%21.97%
Torrent Pharma.₹4,961.5086.101,88,6970.77%364−20.58%4,197+41.84%15.19%
Cipla₹1,410.6031.821,13,8930.92%786−39.19%7,119+2.33%15.49%
Zydus Lifesci.₹1,108.7020.391,10,6130.09%1,341+21.92%7,587+16.22%21.14%
Lupin₹2,370.5019.061,08,4010.76%1,469+101.49%7,475+31.89%29.93%
Mankind Pharma₹2,507.2051.441,03,5590.04%559+34.23%3,443+11.81%13.53%
Median: 157 Co.₹432.0533.931,9700.10%15+28.10%176+17.66%15.10%

Filings

D
Annual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts40
TranscriptMay 2026TranscriptFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025TranscriptMay 2025TranscriptJan 2025TranscriptOct 2024RECOct 2024TranscriptJul 2024TranscriptMay 2024TranscriptFeb 2024TranscriptAug 2023TranscriptMay 2023PPTSep 2022TranscriptMay 2021TranscriptFeb 2021TranscriptOct 2020TranscriptJul 2020TranscriptMay 2020TranscriptOct 2019
Credit ratings6
Rating update 21 JulicraRating update 5 JanicraRating update 2 JanfitchRating update 6 Oct 2025fitchRating update 8 Jul 2025icraRating update 19 Mar 2025icra
Announcements5
Allotment Of 4,19,22,416 Fully Paid-Up Equity Shares Of The Company To The Eligible Shareholders Of J. B. Chemicals & Pharmaceuticals Limited As On The Record Date I.E. 17Th July, 2026, In Terms Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders 20 Jul - Allotted 4.19 crore shares to JB Chemicals shareholders under merger; paid-up capital rises to ₹1,90,18,39,280.Dissolution Of Wholly Owned Subsidiary (WOS) 17 Jul - Curatio Inc., Philippines WOS dissolved effective 10-Jul-26; company notified on 17-Jul-26.ESG Rating 17 Jul - Crisil ESG assigns Torrent Pharma ESG 66 and Core ESG 74.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Jul - Post Quarterly Financial Result Conference call with investors / analystBoard Meeting Intimation for Unaudited Standalone And Consolidated Financial Results (With Limited Review) For The Quarter Ended On 30-Jun-26. 16 Jul - Board meets on 30-Jul-26 to approve Q1 FY27 unaudited standalone and consolidated results.